A pill version of semaglutide — the active ingredient in Ozempic and Wegovy — helped people lose more than 13% of their body weight in a late-stage trial, pharmaceutical giant Novo Nordisk announced on Wednesday, Sept. 17.

The company is calling the medication the “Wegovy pill” and has submitted it for approval to the U.S. Food and Drug Administration.

It comes as rival Eli Lilly is hoping to get its own GLP-1 drug in pill form approved as well.

The drugs mimic GLP-1 , a hormone the body produces after eating, which can decrease appetite and help the body manage insulin production.

People who take this class of medications for weight loss or Type 2 diabetes must currently self-inject the drugs once a week. A pill version could be much more appealing for patients who can’t stand nee

See Full Page